T2 Biosystems Stock Price, News & Analysis (NASDAQ:TTOO)

$3.99 -0.09 (-2.21 %)
(As of 11/18/2017 07:27 AM ET)
Previous Close$3.99
Today's Range$4.05 - $3.92
52-Week Range$2.50 - $6.99
Volume86,175 shs
Average Volume165,606 shs
Market Capitalization$142.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4

About T2 Biosystems (NASDAQ:TTOO)

T2 Biosystems logoT2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.


Industry, Sector and Symbol:
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:TTOO
  • CUSIP: N/A
  • Web: www.t2biosystems.com
Debt:
  • Debt-to-Equity Ratio: 2.25%
  • Current Ratio: 5.40%
  • Quick Ratio: 5.28%
Sales & Book Value:
  • Annual Sales: $4.1 million
  • Price / Sales: 34.87
  • Book Value: $0.51 per share
  • Price / Book: 7.82
Profitability:
  • Trailing EPS: ($1.90)
  • Net Income: ($54,800,000.00)
  • Net Margins: -1,497.70%
  • Return on Equity: -244.82%
  • Return on Assets: -78.53%
Misc:
  • Employees: 178
  • Outstanding Shares: 35,830,000
 

Frequently Asked Questions for T2 Biosystems (NASDAQ:TTOO)

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) issued its quarterly earnings data on Thursday, November, 2nd. The medical equipment provider reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.04. The medical equipment provider earned $1.11 million during the quarter, compared to analyst estimates of $1.10 million. T2 Biosystems had a negative return on equity of 244.82% and a negative net margin of 1,497.70%. T2 Biosystems's revenue for the quarter was up 2.8% compared to the same quarter last year. View T2 Biosystems' Earnings History.

When will T2 Biosystems make its next earnings announcement?

T2 Biosystems is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for T2 Biosystems.

Where is T2 Biosystems' stock going? Where will T2 Biosystems' stock price be in 2017?

6 analysts have issued 12-month target prices for T2 Biosystems' shares. Their predictions range from $4.00 to $12.00. On average, they expect T2 Biosystems' share price to reach $6.83 in the next year. View Analyst Ratings for T2 Biosystems.

What are Wall Street analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:

  • 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (11/8/2017)
  • 2. WBB Securities analysts commented, "We Believe that in the not too distant future, doctors in residency will be trained to detect fungal and bacterial infections in hours with 95% accuracy versus the current blood culture standard of two days on average for invasive candidiasis detection, with 38% accuracy. This is the special province that T2 Biosystems, Inc. (TTOO) presently dominates. We are therefore reiterating our Strong Buy Rating and 12-Month Price Target of $12.00." (2/5/2017)

Who are some of T2 Biosystems' key competitors?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the folowing people:

  • John McDonough, President, Chief Executive Officer, Director (Age 57)
  • Michael J. Cima Ph.D., Co-Founder, Independent Director (Age 57)
  • Darlene Deptula-Hicks, Chief Financial Officer, Senior Vice President, Treasurer (Age 59)
  • Joanne Spadoro Ph.D., Chief Operations Officer (Age 58)
  • Rahul K. Dhanda, Senior Vice President - Corporate Development (Age 44)
  • Thomas J. Lowery Ph.D., Chief Scientific Officer (Age 38)
  • Michael Gibbs, Vice President, General Counsel (Age 46)
  • Michael A. Pfaller M.D., Chief Medical Officer (Age 66)
  • Seymour E. Liebman, Director (Age 68)
  • John W. Cumming, Independent Director (Age 71)

Who owns T2 Biosystems stock?

T2 Biosystems' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Senvest Management LLC (9.32%), Lagoda Investment Management L.P. (8.90%), Essex Investment Management Co. LLC (2.30%), Point72 Asset Management L.P. (0.42%) and Gagnon Securities LLC (0.26%). Company insiders that own T2 Biosystems stock include Aisling Capital Iii Lp, Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro, Michael Terrence Gibbs and Rahul Dhanda. View Institutional Ownership Trends for T2 Biosystems.

Who bought T2 Biosystems stock? Who is buying T2 Biosystems stock?

T2 Biosystems' stock was purchased by a variety of institutional investors in the last quarter, including Lagoda Investment Management L.P., Senvest Management LLC, Essex Investment Management Co. LLC, Point72 Asset Management L.P. and Gagnon Securities LLC. Company insiders that have bought T2 Biosystems stock in the last two years include Aisling Capital Iii Lp, Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro and Michael Terrence Gibbs. View Insider Buying and Selling for T2 Biosystems.

How do I buy T2 Biosystems stock?

Shares of T2 Biosystems can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of T2 Biosystems stock can currently be purchased for approximately $3.99.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $142.94 million and generates $4.1 million in revenue each year. The medical equipment provider earns ($54,800,000.00) in net income (profit) each year or ($1.90) on an earnings per share basis. T2 Biosystems employs 178 workers across the globe.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]


MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  303
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for T2 Biosystems (NASDAQ:TTOO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $6.83 (71.26% upside)

Consensus Price Target History for T2 Biosystems (NASDAQ:TTOO)

Price Target History for T2 Biosystems (NASDAQ:TTOO)

Analysts' Ratings History for T2 Biosystems (NASDAQ:TTOO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017HC WainwrightReiterated RatingBuy$8.00N/AView Rating Details
10/30/2017Canaccord GenuityReiterated RatingBuy$6.00N/AView Rating Details
5/8/2017BTIG ResearchUpgradeSell -> Neutral$4.00HighView Rating Details
5/3/2017Cantor FitzgeraldLower Price TargetOverweight$7.00 -> $6.00HighView Rating Details
3/14/2017Morgan StanleyDowngradeEqual Weight -> Underweight$5.00HighView Rating Details
2/5/2017WBB SecuritiesReiterated RatingBuy$12.00N/AView Rating Details
11/10/2016Leerink SwannReiterated RatingMarket Perform$5.00N/AView Rating Details
7/9/2016Janney Montgomery ScottReiterated RatingHoldN/AView Rating Details
12/22/2015Goldman Sachs Group, Inc. (The)Boost Price TargetNeutral$13.00 -> $14.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for T2 Biosystems (NASDAQ:TTOO)

Earnings by Quarter for T2 Biosystems (NASDAQ:TTOO)

Earnings History by Quarter for T2 Biosystems (NASDAQ TTOO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018($0.42)N/AView Earnings Details
11/2/2017Q3 2017($0.49)($0.45)$1.10 million$1.11 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.49)($0.50)$0.79 million$0.96 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.47)($0.48)$1.55 million$0.94 millionViewListenView Earnings Details
11/1/2016Q3($0.52)($0.51)$2.03 million$1.08 millionViewN/AView Earnings Details
8/1/2016Q2($0.56)($0.58)$1.53 million$0.99 millionViewN/AView Earnings Details
5/2/2016Q1($0.54)($0.55)$1.01 million$1.10 millionViewN/AView Earnings Details
2/16/2016Q4($0.59)($0.56)$1.21 million$1.01 millionViewListenView Earnings Details
11/2/2015Q3($0.59)($0.57)$0.66 million$1.05 millionViewN/AView Earnings Details
8/4/2015Q215($0.57)($0.54)$0.34 million$0.56 millionViewN/AView Earnings Details
5/5/2015Q115($0.57)($0.53)$0.22 million$0.19 millionViewN/AView Earnings Details
2/17/2015Q414($0.44)($0.45)$0.12 millionViewN/AView Earnings Details
11/4/2014Q314($0.58)($0.71)$0.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for T2 Biosystems (NASDAQ:TTOO)
2017 EPS Consensus Estimate: ($2.06)
2018 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.59)($0.59)($0.59)
Q2 20171($0.49)($0.49)($0.49)
Q3 20171($0.49)($0.49)($0.49)
Q4 20171($0.49)($0.49)($0.49)
Q1 20181($0.53)($0.53)($0.53)
Q2 20181($0.50)($0.50)($0.50)
Q3 20181($0.48)($0.48)($0.48)
Q4 20181($0.45)($0.45)($0.45)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for T2 Biosystems (NASDAQ:TTOO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for T2 Biosystems (NASDAQ TTOO)

Insider Ownership Percentage: 38.70%
Institutional Ownership Percentage: 53.39%
Insider Trades by Quarter for T2 Biosystems (NASDAQ:TTOO)
Institutional Ownership by Quarter for T2 Biosystems (NASDAQ:TTOO)

Insider Trades by Quarter for T2 Biosystems (NASDAQ TTOO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2017David B ElsbreeDirectorBuy1,500$4.11$6,165.00View SEC Filing  
6/6/2017Darlene M Deptula-HicksCFOBuy4,000$3.58$14,320.00View SEC Filing  
6/6/2017David B ElsbreeDirectorBuy10,000$3.50$35,000.00View SEC Filing  
6/6/2017Joanne SpadoroCOOBuy5,000$3.50$17,500.00View SEC Filing  
6/6/2017Michael Terrence GibbsGeneral CounselBuy1,000$3.51$3,510.00View SEC Filing  
3/15/2017David B ElsbreeDirectorBuy10,000$5.97$59,700.00View SEC Filing  
6/30/2016Rahul DhandaSVPSell3,589$8.16$29,286.24View SEC Filing  
3/16/2016Rahul DhandaSVPSell7,588$8.01$60,779.88View SEC Filing  
12/9/2015Aisling Capital Iii LpMajor ShareholderBuy307,692$9.75$2,999,997.00View SEC Filing  
12/9/2015David B ElsbreeDirectorBuy10,000$9.75$97,500.00View SEC Filing  
7/24/2015Polaris Venture Partners V, L.Major ShareholderSell15,399$15.04$231,600.96View SEC Filing  
7/22/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$15.22$228,284.78View SEC Filing  
7/21/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$15.42$231,284.58View SEC Filing  
7/20/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$16.05$240,733.95View SEC Filing  
7/17/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$16.26$731,651.22View SEC Filing  
7/14/2015Polaris Venture Partners V, L.Major ShareholderSell29,998$16.57$497,066.86View SEC Filing  
7/10/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$16.25$731,201.25View SEC Filing  
7/10/2015Thomas J LoweryInsiderSell2,000$16.03$32,060.00View SEC Filing  
7/7/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$15.91$715,902.27View SEC Filing  
7/1/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$16.09$724,001.73View SEC Filing  
6/30/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$16.22$243,283.78View SEC Filing  
6/29/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$16.28$244,183.72View SEC Filing  
6/26/2015Polaris Venture Partners V, L.Major ShareholderSell44,997$17.08$768,548.76View SEC Filing  
6/23/2015Polaris Venture Partners V, L.Major ShareholderSell29,998$18.18$545,363.64View SEC Filing  
6/22/2015Polaris Venture Partners V, L.Major ShareholderSell14,999$18.22$273,281.78View SEC Filing  
6/18/2015Thomas J LoweryInsiderSell1,000$18.65$18,650.00View SEC Filing  
6/12/2015Michael J CimaDirectorBuy1,000$18.91$18,910.00View SEC Filing  
6/12/2015Thomas J LoweryInsiderSell1,471$18.55$27,287.05View SEC Filing  
5/8/2015Michael A PfallerInsiderSell15,440$16.31$251,826.40View SEC Filing  
4/20/2015Thomas J LoweryInsiderSell1,000$18.43$18,430.00View SEC Filing  
3/4/2015David B ElsbreeDirectorBuy1,450$15.05$21,822.50View SEC Filing  
11/13/2014David B ElsbreeDirectorBuy1,500$14.75$22,125.00View SEC Filing  
8/12/2014Aisling Capital Iii LpMajor ShareholderBuy454,545$11.00$4,999,995.00View SEC Filing  
8/12/2014Sarah O KalilCOOBuy15,000$11.00$165,000.00View SEC Filing  
8/12/2014Thomas J CarellaDirectorBuy909,090$11.00$9,999,990.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for T2 Biosystems (NASDAQ TTOO)

Source:
DateHeadline
T2 Biosystems, Inc. (TTOO) Receives Average Recommendation of "Hold" from AnalystsT2 Biosystems, Inc. (TTOO) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 19 at 4:02 AM
Zacks: Brokerages Expect T2 Biosystems, Inc. (TTOO) Will Post Quarterly Sales of $1.15 MillionZacks: Brokerages Expect T2 Biosystems, Inc. (TTOO) Will Post Quarterly Sales of $1.15 Million
www.americanbankingnews.com - November 11 at 2:32 AM
 Analysts Expect T2 Biosystems, Inc. (TTOO) Will Post Earnings of -$0.43 Per Share Analysts Expect T2 Biosystems, Inc. (TTOO) Will Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - November 9 at 7:15 PM
T2 Biosystems Announces Presentation on T2Sepsis Solution at AMP 2017 - GlobeNewswire (press release)T2 Biosystems Announces Presentation on T2Sepsis Solution at AMP 2017 - GlobeNewswire (press release)
globenewswire.com - November 9 at 8:48 AM
ETFs with exposure to T2 Biosystems, Inc. : November 8, 2017ETFs with exposure to T2 Biosystems, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 8:48 AM
T2 Biosystems Announces Presentation on T2Sepsis Solution at AMP 2017T2 Biosystems Announces Presentation on T2Sepsis Solution at AMP 2017
finance.yahoo.com - November 9 at 8:48 AM
T2 Biosystems, Inc. :TTOO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017T2 Biosystems, Inc. :TTOO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 12:35 PM
HC Wainwright Reaffirms Buy Rating for T2 Biosystems, Inc. (TTOO)HC Wainwright Reaffirms Buy Rating for T2 Biosystems, Inc. (TTOO)
www.americanbankingnews.com - November 5 at 6:20 PM
T2 Biosystems, Inc. to Host Earnings CallT2 Biosystems, Inc. to Host Earnings Call
finance.yahoo.com - November 5 at 7:42 AM
T2 Biosystems Reports Third Quarter 2017 Financial Results and Provides Company UpdateT2 Biosystems Reports Third Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - November 5 at 7:42 AM
T2 Biosystems reports 3Q lossT2 Biosystems reports 3Q loss
finance.yahoo.com - November 5 at 7:42 AM
Edited Transcript of TTOO earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of TTOO earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 5 at 7:42 AM
T2 Biosystems, Inc. (TTOO) Issues Quarterly  Earnings Results, Beats Expectations By $0.04 EPST2 Biosystems, Inc. (TTOO) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - November 3 at 3:22 PM
T2 Biosystems to Attend the Canaccord Medical Technologies and Diagnostics Forum - GlobeNewswire (press release)T2 Biosystems to Attend the Canaccord Medical Technologies and Diagnostics Forum - GlobeNewswire (press release)
globenewswire.com - November 1 at 9:59 AM
T2 Biosystems to Attend the Canaccord Medical Technologies and Diagnostics ForumT2 Biosystems to Attend the Canaccord Medical Technologies and Diagnostics Forum
finance.yahoo.com - November 1 at 9:58 AM
T2 Biosystems, Inc. (TTOO) Receives Average Recommendation of "Hold" from BrokeragesT2 Biosystems, Inc. (TTOO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 25 at 5:02 AM
T2 Biosystems, Inc. (TTOO) Expected to Announce Quarterly Sales of $1.09 MillionT2 Biosystems, Inc. (TTOO) Expected to Announce Quarterly Sales of $1.09 Million
www.americanbankingnews.com - October 23 at 1:24 PM
T2 Biosystems, Inc. (TTOO) Scheduled to Post Quarterly Earnings on MondayT2 Biosystems, Inc. (TTOO) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 11:18 AM
-$0.48 Earnings Per Share Expected for T2 Biosystems, Inc. (TTOO) This Quarter-$0.48 Earnings Per Share Expected for T2 Biosystems, Inc. (TTOO) This Quarter
www.americanbankingnews.com - October 21 at 2:22 AM
T2 Biosystems Announces 2017 Third Quarter Financial and Operational Results Release and Conference Call DateT2 Biosystems Announces 2017 Third Quarter Financial and Operational Results Release and Conference Call Date
finance.yahoo.com - October 17 at 8:25 AM
ETFs with exposure to T2 Biosystems, Inc. : October 13, 2017ETFs with exposure to T2 Biosystems, Inc. : October 13, 2017
finance.yahoo.com - October 14 at 8:51 AM
Clinicians Discuss Positive Impact of T2MR Platform on Sepsis Care at IDWeek 2017Clinicians Discuss Positive Impact of T2MR Platform on Sepsis Care at IDWeek 2017
finance.yahoo.com - October 13 at 9:36 AM
DexCom (DXCM) and T2 Biosystems (TTOO) Critical AnalysisDexCom (DXCM) and T2 Biosystems (TTOO) Critical Analysis
www.americanbankingnews.com - October 12 at 8:08 PM
T2 Biosystems (TTOO) vs. Its Rivals Financial AnalysisT2 Biosystems (TTOO) vs. Its Rivals Financial Analysis
www.americanbankingnews.com - October 8 at 12:28 PM
T2 Biosystems, Inc. (TTOO) Upgraded to Hold by Zacks Investment ResearchT2 Biosystems, Inc. (TTOO) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - October 7 at 11:54 PM
T2 Biosystems Inc (TTOO) Expected to Post Quarterly Sales of $1.09 MillionT2 Biosystems Inc (TTOO) Expected to Post Quarterly Sales of $1.09 Million
www.americanbankingnews.com - October 4 at 1:56 PM
Study Published in Journal of Antimicrobial Stewardship Shows Patients Diagnosed with T2Candida Panel Treated More Than Eight Times FasterStudy Published in Journal of Antimicrobial Stewardship Shows Patients Diagnosed with T2Candida Panel Treated More Than Eight Times Faster
finance.yahoo.com - October 3 at 2:01 PM
T2 Biosystems, Inc. (TTOO) Receives Average Rating of "Hold" from AnalystsT2 Biosystems, Inc. (TTOO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 30 at 5:12 AM
T2 Biosystems Announces Presentations at IDWeek 2017T2 Biosystems Announces Presentations at IDWeek 2017
finance.yahoo.com - September 23 at 10:20 AM
T2 Biosystems to Present at the Cantor Fitzgerald Global Healthcare ConferenceT2 Biosystems to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 19 at 8:50 AM
T2 Biosystems (TTOO) Prices 4.38M Common Stock Offering at $4/ShareT2 Biosystems (TTOO) Prices 4.38M Common Stock Offering at $4/Share
www.streetinsider.com - September 17 at 8:51 AM
T2 Biosystems (TTOO) and Its Competitors Head to Head ReviewT2 Biosystems (TTOO) and Its Competitors Head to Head Review
www.americanbankingnews.com - September 17 at 8:20 AM
T2 Biosystems Prices Secondary OfferingT2 Biosystems Prices Secondary Offering
finance.yahoo.com - September 16 at 9:55 AM
Invacare Corporation (IVC) and T2 Biosystems (TTOO) Head-To-Head ReviewInvacare Corporation (IVC) and T2 Biosystems (TTOO) Head-To-Head Review
www.americanbankingnews.com - September 15 at 8:46 PM
T2 Biosystems Announces Proposed Public Offering of Common StockT2 Biosystems Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 15 at 10:22 AM
T2 Biosystems Announces Pricing of Public Offering of Common StockT2 Biosystems Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 15 at 10:22 AM
T2 Biosystems stock sinks on heavy volume after share offering prices at deep discountT2 Biosystems' stock sinks on heavy volume after share offering prices at deep discount
finance.yahoo.com - September 15 at 10:22 AM
$1.09 Million in Sales Expected for T2 Biosystems, Inc. (TTOO) This Quarter$1.09 Million in Sales Expected for T2 Biosystems, Inc. (TTOO) This Quarter
www.americanbankingnews.com - September 15 at 7:10 AM
With FDA filing, Lexington firm targets a scourge of hospitals: sepsisWith FDA filing, Lexington firm targets a scourge of hospitals: sepsis
finance.yahoo.com - September 13 at 10:30 AM
T2 Biosystems Submits 510(k) Application to the FDA for Review of T2Bacteria PanelT2 Biosystems Submits 510(k) Application to the FDA for Review of T2Bacteria Panel
finance.yahoo.com - September 12 at 11:24 AM
T2 Biosystems Announces Collaboration with CDC to Detect Emerging Superbug Candida aurisT2 Biosystems Announces Collaboration with CDC to Detect Emerging Superbug Candida auris
finance.yahoo.com - September 6 at 9:27 AM
T2 Biosystems and Cidara Therapeutics Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug TrialsT2 Biosystems and Cidara Therapeutics Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug Trials
finance.yahoo.com - September 6 at 9:27 AM
T2 Biosystems, Inc. (TTOO) Given Average Rating of "Hold" by BrokeragesT2 Biosystems, Inc. (TTOO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 5 at 4:56 AM
ETFs with exposure to T2 Biosystems, Inc. : September 1, 2017ETFs with exposure to T2 Biosystems, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 10:08 AM
T2 Biosystems Announces 11 New Patents Granted in 2017T2 Biosystems Announces 11 New Patents Granted in 2017
finance.yahoo.com - August 31 at 11:20 AM
T2 Biosystems, Inc. :TTOO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017T2 Biosystems, Inc. :TTOO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:54 AM
T2 Biosystems and Aridis Pharmaceuticals, Inc. Join Antimicrobials Working GroupT2 Biosystems and Aridis Pharmaceuticals, Inc. Join Antimicrobials Working Group
finance.yahoo.com - August 16 at 8:28 AM
T2 Biosystems, Inc. (NASDAQ:TTOO) Sees Large Growth in Short InterestT2 Biosystems, Inc. (NASDAQ:TTOO) Sees Large Growth in Short Interest
www.americanbankingnews.com - August 13 at 2:20 AM
Edited Transcript of TTOO earnings conference call or presentation 3-Aug-17 8:30pm GMTEdited Transcript of TTOO earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 12 at 1:27 AM
T2 Biosystems, Inc. (TTOO) Given Consensus Rating of "Hold" by AnalystsT2 Biosystems, Inc. (TTOO) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - August 11 at 10:56 AM

Social Media

Financials

Chart

T2 Biosystems (NASDAQ TTOO) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.